Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
about
Fibulin-3 as a biomarker of response to treatment in malignant mesotheliomaRandomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenoc[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients.Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Outcome of severe infections in afebrile neutropenic cancer patients.Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival.Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase InhibitorsUpregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer.
P2860
Q28389185-67DF5B43-C872-4B1A-B3B3-89087F0FFD80Q35817772-A2E6F6B0-28C3-46E3-AB1F-6D11AF3DFDDDQ36490370-31B0DBB6-D52F-463E-AFF2-48211D94EF0AQ37357699-A7F431F1-3060-4636-85E2-29ED9B4043D1Q37432031-ADDBC3BF-0E37-47E7-B90F-B62113DFF400Q37624187-B1EF0668-FF06-4569-927D-A3B16E1237EBQ38663388-CCD6EAE0-203F-42DA-9A98-10E82C5B4409Q38983980-035E7CAA-1B05-46D1-995E-949F8E116A0CQ41678123-1799A3E0-31BB-48A2-B533-142310A96705Q52565512-474922AF-A66C-40C0-A408-EFB895BEB1C7
P2860
Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Intercalated chemotherapy and ...... with EGFR activating mutations
@ast
Intercalated chemotherapy and ...... with EGFR activating mutations
@en
Intercalated chemotherapy and ...... with EGFR activating mutations
@nl
type
label
Intercalated chemotherapy and ...... with EGFR activating mutations
@ast
Intercalated chemotherapy and ...... with EGFR activating mutations
@en
Intercalated chemotherapy and ...... with EGFR activating mutations
@nl
prefLabel
Intercalated chemotherapy and ...... with EGFR activating mutations
@ast
Intercalated chemotherapy and ...... with EGFR activating mutations
@en
Intercalated chemotherapy and ...... with EGFR activating mutations
@nl
P2093
P2860
P356
P1476
Intercalated chemotherapy and ...... with EGFR activating mutations
@en
P2093
Izidor Kern
Karmen Stanic
Martina Vrankar
Matjaz Zwitter
Mirjana Rajer
Natalija Edelbaher
Viljem Kovac
P2860
P304
P356
10.2478/RAON-2014-0038
P577
2014-11-05T00:00:00Z